Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Kim

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
World Journal of Gastrointestinal Oncology|March 25, 2020
FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort studyAngélique Vienot, Hortense Chevalier, Clément Bolognini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialJulien Taïeb, Thierry André, Farid El Hajbi, et al.
BMC Cancer|October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric studyChristelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
World Journal of Clinical Oncology|September 27, 2018
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancerCandice Carola, François Ghiringhelli, Stefano Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patientsLaura Mansi, Laurie Spehner, Etienne Daguindau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO GuidelineVan K Morris, Erin B Kennedy, Manik A Amin, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
Frontiers in Oncology|September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinomaStefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
World Journal of Gastrointestinal Oncology|March 25, 2020
FOLFOXIRI <i>vs</i> FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort studyAngélique Vienot, Hortense Chevalier, Clément Bolognini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialJulien Taïeb, Thierry André, Farid El Hajbi, et al.
BMC Cancer|October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric studyChristelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
World Journal of Clinical Oncology|September 27, 2018
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancerCandice Carola, François Ghiringhelli, Stefano Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patientsLaura Mansi, Laurie Spehner, Etienne Daguindau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO GuidelineVan K Morris, Erin B Kennedy, Manik A Amin, et al.
The Lancet. Oncology|November 7, 2025
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trialStefano Kim, Jihane Boustani, Soledad Iseas, et al.
Cancer Chemotherapy and Pharmacology|May 15, 2014
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancerMarine Jary, Francois Ghiringhelli, Marion Jacquin, et al.
Frontiers in Oncology|September 19, 2022
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinomaStefano Kim, Jihane Boustani, Dewi Vernerey, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Pageof 7